News on Serono Japan Company Limited from BioPortfolio.com http://www.BioPortfolio.com Consolidated Serono Japan Company Limited news from BioPortfolio.com Tue, 09 Feb 2010 15:01:24 GMT en Daiichi Sankyo Submits a New Drug Application in Japan for CS-8958, a Long-Acting Neuraminidase Inhibitor forhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4010172&HITNO=0&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4010172&THISHREF=http://c.moreover.com/click/here.pl%3fz2522277779%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4010172&HITNO=0&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4010172&THISHREF=http://c.moreover.com/click/here.pl%3fz2522277779%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Phase Forward to Speak at Key Industry Events in Februaryhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4016301&HITNO=1&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4016301&THISHREF=http://c.moreover.com/click/here.pl%3fz2524709035%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4016301&HITNO=1&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4016301&THISHREF=http://c.moreover.com/click/here.pl%3fz2524709035%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmiWeb: BRIEF-Glaxo appoints Philippe Fauchet president GSK Japanhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4015100&HITNO=2&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4015100&THISHREF=http://c.moreover.com/click/here.pl%3fz2524273969%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4015100&HITNO=2&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4015100&THISHREF=http://c.moreover.com/click/here.pl%3fz2524273969%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comInteractive Investor: First Treatment To Improve Survival In 20 Years Now Available For Patients With Osteosarcoma (Bone Cancer)http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4007457&HITNO=3&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4007457&THISHREF=http://c.moreover.com/click/here.pl%3fz2521141699%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4007457&HITNO=3&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4007457&THISHREF=http://c.moreover.com/click/here.pl%3fz2521141699%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Preventiohttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4004341&HITNO=4&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4004341&THISHREF=http://c.moreover.com/click/here.pl%3fz2519908591%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4004341&HITNO=4&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4004341&THISHREF=http://c.moreover.com/click/here.pl%3fz2519908591%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: First Treatment to Improve Survival in 20 Yearshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3995554&HITNO=5&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3995554&THISHREF=http://c.moreover.com/click/here.pl%3fz2515731023%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3995554&HITNO=5&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3995554&THISHREF=http://c.moreover.com/click/here.pl%3fz2515731023%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmiWeb: Immunocore Limited announces appointment of Dr Jonathan Knowles to the Boardhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3995223&HITNO=6&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3995223&THISHREF=http://c.moreover.com/click/here.pl%3fz2515541438%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3995223&HITNO=6&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3995223&THISHREF=http://c.moreover.com/click/here.pl%3fz2515541438%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: First Treatment to Improve Survival in 20 Years Now Available for Patients with Osteosarcoma (Bone Cancer)http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3990400&HITNO=7&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3990400&THISHREF=http://c.moreover.com/click/here.pl%3fz2513300784%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3990400&HITNO=7&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3990400&THISHREF=http://c.moreover.com/click/here.pl%3fz2513300784%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comAsahi.com: Immunocore Limited announces appointment of Dr Jonathan Knowles to the Boardhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3994169&HITNO=8&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3994169&THISHREF=http://c.moreover.com/click/here.pl%3fz2514902015%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3994169&HITNO=8&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3994169&THISHREF=http://c.moreover.com/click/here.pl%3fz2514902015%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Uptake of the first oral MS therapies will result in the market value peaking at $8.4 billion in 2013http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3992577&HITNO=9&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3992577&THISHREF=http://c.moreover.com/click/here.pl%3fz2514248799%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3992577&HITNO=9&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3992577&THISHREF=http://c.moreover.com/click/here.pl%3fz2514248799%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Letter: Daiichi Sankyo submits a New Drug Application in Japan for CS-8958http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3991441&HITNO=10&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3991441&THISHREF=http://c.moreover.com/click/here.pl%3fz2513708360%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3991441&HITNO=10&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3991441&THISHREF=http://c.moreover.com/click/here.pl%3fz2513708360%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBioPortfolio: Wipro and Trend Micro Unite to Deliver Next-Generation Virtualization Security Solutions for Dynamic Datacentershttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3990373&HITNO=11&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3990373&THISHREF=http://c.moreover.com/click/here.pl%3fz2513292283%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3990373&HITNO=11&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3990373&THISHREF=http://c.moreover.com/click/here.pl%3fz2513292283%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFreshnews.com: Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel inhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3988668&HITNO=12&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3988668&THISHREF=http://c.moreover.com/click/here.pl%3fz2511336157%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3988668&HITNO=12&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3988668&THISHREF=http://c.moreover.com/click/here.pl%3fz2511336157%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comJournal of Clinical Pharmacology: Lupin Receives U.S. FDA Approval For Perindopril Erbumine Tabletshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3987746&HITNO=13&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3987746&THISHREF=http://c.moreover.com/click/here.pl%3fz2510050482%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3987746&HITNO=13&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3987746&THISHREF=http://c.moreover.com/click/here.pl%3fz2510050482%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Research and Markets: Pipeline Insight: Multiple Sclerosis - The Uptake of the First Oral Therapies to Result In the Market Value Peaking At $8.4 Billion in 2013http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3987994&HITNO=14&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3987994&THISHREF=http://c.moreover.com/click/here.pl%3fz2510359825%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3987994&HITNO=14&MSIZE=86&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Serono%20Japan%20Company%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3987994&THISHREF=http://c.moreover.com/click/here.pl%3fz2510359825%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSmartBrief: